Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,188 total articles
Cummins is no longer just an engine maker. Its Power Systems business is delivering high-single-digit to double-digit growth, record margins and a multi-year backlog as hyperscalers pour capital into AI infrastructure. With shares trading below key moving averages and an RSI in oversold territory, the setup offers a tactical long with defined risk …
Kennametal (KMT) trades at roughly a 6.7x P/E with EV/EBITDA under 5 and generates double-digit ROE while paying a 2.6% yield. Short-term negatives — volatile tungsten pricing and a quarter of negative free cash flow — are real, but the valuation gap and operational strength make a downgrade premature. This is a mid-term trade for disciplined buyer…
Sasol's earnings power is highly sensitive to feedstock costs. If ethane/natural gas prices and logistics improve, the company can outperform a plain commodity rebound thanks to margin expansion in chemicals and fuels. This trade targets that asymmetric upside with disciplined risk control.
Cryoport (CYRX) is a primary beneficiary of the commercial rollout of cell and gene therapies. With Q1 2026 revenue up 16% y/y, commercial CGT revenue up 26% and management raising full-year guidance to $192-196M, the setup favors a long trade. Entry at $17.40, stop at $14.50, target $30.00 over a long-term horizon (180 trading days).
A sharp pullback has trimmed stretched expectations for Centrus. The company's $4.5B backlog, intact 2026 revenue guidance and unique position in HALEU supply justify an upgraded, tactical long with defined risk controls. This trade targets a rebound toward fairer multiples while respecting execution risk and cash flow weakness.
Flowers Foods (FLO) sits at 52-week lows and an oversold technical profile. The stock offers a high nominal yield and cheap valuation metrics on free cash flow, but the company is navigating volume declines, elevated input and distribution costs, and a push to deleverage. This trade idea proposes a defined-entry long to capture a mid-term mean-reve…
Muse, Meta's new personal AI agent, is rapidly moving up app-store charts and is being integrated into AI glasses and core apps. This trade idea buys into the view that Muse will both generate subscription revenue and materially increase ad pricing by surfacing high-intent signals previously dominated by search and commerce platforms. Entry $777.44…
SharkNinja combines category-leading products and accelerating top-line momentum with a healthy free-cash profile and manageable capital structure. Recent results and a raised guide point to sustained growth across Cleaning, Cooking & Beverage, Food Prep and Beauty - making the stock a buy for patient investors. I outline an actionable long-term tr…
Berkshire offers a low-PE, hard-asset-heavy portfolio with growing exposure to hyperscalers and Japanese equities. Valuation and cash-flow metrics look reasonable relative to its asset mix; we recommend a mid-term long with an entry at $506, a stop at $485 and a target at $540 (45 trading days).
Unity Bancorp has pulled back into an oversold range at roughly $55 while reporting strong 2025 earnings, double-digit loan and deposit growth, and expanded small-business lending access via NJEDA. Valuation is reasonable (P/E ~10, P/B ~1.54) and capital metrics support a continued run higher. This trade idea sets a disciplined entry, stop and targ…
Chevron offers a compelling long-term risk/reward: strong free cash flow ($27.0B), a 3.43% yield supported by a 39-year streak of dividend growth, and a conservative balance sheet (debt/equity 0.20). We lay out an actionable 180‑day trade with clear entry, target and stop.
Meta's Muse rollout alters both the revenue runway and competitive dynamics. We upgrade the rating to a tactical buy: enter at $650.00, target $780.00, stop $560.00. The trade is driven by accelerating ad relevance, new commerce touchpoints, and a lower capital drag from Reality Labs as AI adoption scales. Risks include execution, regulation, and m…
Pfizer offers a mix of reliable cash generation, a 6.1% yield and an advancing R&D pipeline tied to autoimmune and vaccine-adjuvant innovation. At $28.44, the stock sits between its 52-week low and high and shows constructive technicals. This trade ideas targets a mid-term upside while protecting capital with a clear stop.
AC Immune (ACIU) is a clinical-stage neurodegeneration company trading at a $275m market cap. With recent price action near $2.70, modest technical support, and concentrated short interest, the risk/reward looks favorable for a mid-term swing ahead of ongoing ACI-7104 progress and potential pipeline expansion updates. This trade plan lays out an en…
Brookfield Corporation offers a pragmatic path to high shareholder returns: diverse fee-bearing asset management plus a large operating platform that benefits from asset recycling and selective acquisitions. At $36.56, Brookfield trades below key moving averages with an oversold RSI, a recent bolt-on acquisition that supports growth, and a market c…
Honeywell is trading cheap on headline multiples while its higher-margin software and building-automation exposures sit at the front end of multi-year secular growth. The recent post-spin reset and durable cash generation create a favorable risk-reward for a long, with a clear entry, stop and target over a 180 trading day horizon.
CRISPR Therapeutics is a clinical-stage gene-editing company whose shares have recently been buoyed by headlines around an AI developer's discovery that appears to accelerate protein and guide-RNA design. The combination of accelerating commercial revenue from Casgevy, improving margins, and a still-substantial valuation gap makes CRSP a tradable l…
McDonald's pulled back sharply after investor-day positioning, leaving the stock trading near its recent low with an oversold RSI and a 3.1% yield. Fundamentals remain intact: $7.4B in free cash flow, $12.42 EPS and a PE near 19.4. This trade idea lays out a swing buy plan with strict risk controls and a multi-horizon playbook.
Celestica (CLS) looks set to translate 2026 momentum into a 2027 growth phase driven by hyperscale AI demand and an expanding HealthTech portfolio. Fundamentals show improving margins, strong analyst revisions, and healthy cash generation — but the stock trades at a premium and execution risks remain. I lay out a long trade with entry, stop and tar…
DuPont (DD) combines a lean balance sheet, $1.05B of free cash flow and exposure to advanced materials end markets that are expanding on secular trends. At $131, the stock offers upside to prior highs if margins normalize and higher-value mix gains traction. We lay out an actionable long-term trade with entry, stop and target and the key catalysts …
AST SpaceMobile sits at the intersection of cellular and space infrastructure with patents that enable standard phones to connect directly to satellites. The stock trades on growth expectations, not today’s revenue; with $3.7B of reported liquidity and a pushed commercial launch to 2027, the setup is a clear binary trade. I am long with an entry at…
Western Digital (WDC) is trading well below levels justified by its cash generation, AI-driven demand growth and supply tightness for high-capacity storage. We lay out a long trade with concrete entry, stop and target, plus the catalysts and risks that could move the stock over the next 180 trading days.
Bitdeer is transitioning from a pure-play Bitcoin miner into a hybrid miner + AI colocation operator. Recent announcements of long-dated GPU leases (including a 16-year Tydal deal and multi-year Malaysian and A202 commitments) create a recurring revenue backbone. At a market cap of roughly $3.3B and AI Cloud ARR around $86M, the stock looks like a …
Kanzhun (BOSS Zhipin) is showing accelerating monetization after years of investment in product and AI. Q2 revenue growth of 14.1% with operating income up 32.6%, a growing shareholder-return program (> $530m combined) and a clear dividend/buyback commitment justify a long trade from current levels. Entry $14.32, target $18.00, stop $12.50; long te…
ANI Pharmaceuticals (ANIP) combines a cash-generative generics and established brands engine with an optionality-rich rare disease franchise centered on Cortrophin Gel. The stock trades at roughly $1.7B market cap, an EV/sales of ~2.0 and P/E in the mid-teens while management pushes toward $1B+ revenue. If a Q4 readout or commercial update for Cort…
